Literature DB >> 9333269

Prenatal genetic carrier testing using triple disease screening.

C M Eng1, C Schechter, J Robinowitz, G Fulop, T Burgert, B Levy, R Zinberg, R J Desnick.   

Abstract

CONTEXT: Rapid progress in gene discovery has dramatically increased diagnostic capabilities for carrier screening and prenatal testing for genetic diseases. However, simultaneous prenatal carrier screening for prevalent genetic disease has not been evaluated, and patient acceptance and attitudes toward this testing strategy remain undefined.
OBJECTIVE: To evaluate an educational, counseling, and carrier testing program for 3 genetic disorders: Tay-Sachs disease (TSD), type 1 Gaucher disease (GD), and cystic fibrosis (CF) that differ in detectability, severity, and availability of therapy.
DESIGN: Potential participants received education and genetic counseling, gave informed consent, chose screening tests, and completed pre-education and posteducation questionnaires that assessed knowledge, attitudes toward genetic testing, and disease testing preferences.
SETTING: Medical genetics referral center. PATIENTS: Volunteer sample of 2824 Ashkenazi Jewish individuals enrolled as couples who were referred for TSD testing. INTERVENTION: Genetic counseling, education, and if chosen, genetic testing for any or all 3 disorders. MAIN OUTCOME MEASURE: Acceptance of screening for each of the 3 disorders. Secondary outcomes include attitudes toward genetic testing and reproductive considerations.
RESULTS: Of the 2824 individuals tested for TSD, 97% and 95% also chose testing for CF and GD, respectively. The frequency of detected carriers was 1:21 for TSD, 1 :25 for CF, and 1:18 for GD. Twenty-one carriercoupleswere identified, counseled, and all postconception couples opted for prenatal diagnosis. Pre-education and posteducation questionnaires revealed that patients initially knew little about the diseases, but acquired disease information and increased knowledge of genetic concepts. Education and genetic counseling increased understanding and retention of genetic concepts and disease-related information, and minimized test-related anxiety. Although individuals sought screening for all 3 diseases, reproductive attitudes and decisions varied directly with disease severity and treatability.
CONCLUSIONS: These findings emphasize the importance of genetic counseling for prenatal carrier testing and may improve understanding, acceptance, and informed decision making for prenatal carrier screening for multiple genetic diseases.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction; Mount Sinai Medical Center (New York City)

Mesh:

Year:  1997        PMID: 9333269

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  16 in total

1.  Consumers' desire towards current and prospective reproductive genetic testing.

Authors:  Feighanne Hathaway; Esther Burns; Harry Ostrer
Journal:  J Genet Couns       Date:  2009-01-22       Impact factor: 2.537

2.  Platelet hexosaminidase a enzyme assay effectively detects carriers missed by targeted DNA mutation analysis.

Authors:  Sachiko Nakagawa; Jie Zhan; Wei Sun; Jose Carlos Ferreira; Steven Keiles; Tina Hambuch; Anja Kammesheidt; Brian L Mark; Adele Schneider; Susan Gross; Nicole Schreiber-Agus
Journal:  JIMD Rep       Date:  2012-01-31

3.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

4.  Clinico-hematological profile of lysosomal storage disorders - a report of three cases.

Authors:  Sunita Sharma; Mukta Pujani; Priya Malhan; Aparna Harbhajanka; Manjula Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2008-08-24       Impact factor: 0.900

5.  The changing landscape of carrier screening: expanding technology and options?.

Authors:  Michelle L McGowan; Deborah Cho; Richard R Sharp
Journal:  Health Matrix Clevel       Date:  2013

6.  Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations.

Authors:  G A Diaz; B D Gelb; N Risch; T G Nygaard; A Frisch; I J Cohen; C S Miranda; O Amaral; I Maire; L Poenaru; C Caillaud; M Weizberg; P Mistry; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-04-21       Impact factor: 11.025

7.  Preconception carrier screening for multiple disorders: evaluation of a screening offer in a Dutch founder population.

Authors:  Inge B Mathijssen; Kim C A Holtkamp; Cecile P E Ottenheim; Janneke M C van Eeten-Nijman; Phillis Lakeman; Hanne Meijers-Heijboer; Merel C van Maarle; Lidewij Henneman
Journal:  Eur J Hum Genet       Date:  2018-01-10       Impact factor: 4.246

8.  Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.

Authors:  Manisha Balwani; Laura Fuerstman; Ruth Kornreich; Lisa Edelmann; Robert J Desnick
Journal:  Arch Intern Med       Date:  2010-09-13

9.  Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Edward Kloza; Elaine Sugarman; Barbara Pettersen; Trisha Brown; Kim Jensen; Seth Marcus; Joy Redman
Journal:  J Genet Couns       Date:  2005-02       Impact factor: 2.537

10.  The Ashkenazic Jewish Bloom syndrome mutation blmAsh is present in non-Jewish Americans of Spanish ancestry.

Authors:  N A Ellis; S Ciocci; M Proytcheva; D Lennon; J Groden; J German
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.